A Half Century of Technical Development and Trust
[1963-]
| 1963 |
- Taiho Pharmaceutical Co., Ltd. established; Yukio Kobayashi appointed as president and representative director
- Capital increased to ¥100 million
- A representative from each of the 49 distributors nationwide assumes the position of Board Member
|
|---|
| 1964 |
- In-house production plant established in Naruto, Tokushima Prefecture
- Nine new offices established throughout Japan, centered around the head office in Tokyo, as sales bases
|
|---|
| 1965 |
- Capital increased from ¥100 million to ¥200 million
|
|---|
| 1969 |
- License with the Soviet Union to introduce Futraful in Japan
|
|---|
| 1971 |
- Lyophilized formulation plant (seventh plant) completed in the Imagire Industrial Park in Tokushima
|
|---|
[1973-]
| 1974 |
- Proprietary Medicine Division established
|
|---|
| 1975 |
- Advertising strategy (TV ads) started for Tiovita Drink
|
|---|
| 1976 |
- Business alliance formed with Nichiban Co., Ltd., with equity participation by Taiho Pharmaceutical
|
|---|
| 1977 |
- Employee welfare facility Otsuka Amagi Mountain Villa completed
|
|---|
| 1978 |
- Business alliance formed with Kotai Kasei Co., Ltd., with equity participation by Taiho Pharmaceutical
- GMP-compliant injection drug plant completed within the Tokushima Plant; full plant integration also completed
|
|---|
| 1979 |
- Advertising strategy (TV ads) started for Solmack
|
|---|
| 1980 |
- GLP-compliant Development Laboratory and Safety Laboratory completed in Tokushima
|
|---|
[1983-]
| 1985 |
- 100% Taiho-financed Kotai Kasei head office plant completed; Kodama Laboratory set up on the plant premises
|
|---|
| 1986 |
- Head office moved to new building in Kanda, Chiyodaku, Tokyo
- State-of-the-art factory automation plant completed at Tokushima Plant
|
|---|
| 1987 |
- Synphar Laboratory established in Alberta, Canada
- 25th Anniversary Ceremony held in Tokyo and Tokushima
- Akihiko Otsuka becomes chairman and representative director
|
|---|
| 1989 |
- Formulation Research Laboratory completed
|
|---|
| 1990 |
- Drug Discovery Center, Seminar and Training Center, and Computer Center completed in Saitama
- Taiho Pharmaceutical purchases equity and participates in management of Shinsen Iyaku Co., Ltd.
|
|---|
| 1991 |
|
|---|
| 1992 |
- 30th Anniversary Ceremony held in Tokyo
- Name of Shinsen Iyaku Co., Ltd. changed to Okayama Taiho Pharmaceutical Co., Ltd.
- President Yukio Kobayashi awarded honorary doctorate by the University of Alberta in Canada
- Kotai Kasei changed name to Taiho Fine Chemical
|
|---|
[1993-]
| 1994 |
- President Yukio Kobayashi awarded Japan's prestigious Medal with Yellow Ribbon
|
|---|
| 1995 |
- Taiho Fine Chemical merges with Taiho Pharmaceutical and starts operating as Saitama Plant
- President Yukio Kobayashi awarded the GreenDex Award by the Republic of Latvia
|
|---|
| 1996 |
- Collaborative research agreement signed for breast cancer therapeutics with SRI International (US)
|
|---|
| 1997 |
- Japanese and international GMP-compliant plant for new investigational drugs opens
- Clinical Research USA Office established in New York
|
|---|
| 1998 |
- Collaborative research and development agreement for angiogenesis inhibitor signed with Sugen, Inc. (U.S.A.)
|
|---|
| 1999 |
- Yukio Kobayashi, president and representative director of Taiho Pharmaceutical, becomes president and representative director of Otsuka Pharmaceutical Co., Ltd.
|
|---|
| 2000 |
- President Yukio Kobayashi becomes advisor to Otsuka Pharmaceutical
|
|---|
| 2001 |
- Yukio Kobayashi becomes chairman and representative director of Taiho Pharmaceutical
- Toru Usami becomes president and representative director of Taiho Pharmaceutical
|
|---|
| 2002 |
- Company History published in commemoration of the 40th Anniversary
- Taiho Pharma U.S.A., Inc. (now Taiho Oncology, Inc.) established in New Jersey in the U.S.
|
|---|
[2003-]
| 2003 |
- Marketing approval for TS-1 obtained in South Korea
- Inuyama Plant in Aichi Prefecture starts operations
|
|---|
| 2004 |
- Taiho Pharmaceutical signs a licensing agreement for new antiemetic palonosetron with Helsinn Healthcare SA (Switzerland)
- Collaboration agreement in oncology signed with the University of Tokushima
|
|---|
| 2005 |
- Taiho Pharmaceutical signs a licensing agreement for anticancer agent Abraxane with American BioSciences Inc.
|
|---|
| 2007 |
- Annex to the head office completed
- Taiho Pharmaceutical holds a ceremony for the 45th anniversary of its founding in Tokyo
- Tenth plant newly established to manufacture anticancer granules and investigational drugs
|
|---|
| 2008 |
- Otsuka Holdings established
- Taiho Pharmaceutical of Beijing Co., Ltd., established
|
|---|
| 2009 |
- Marketing approval for TS-1 obtained in China
- Taiho Pharmaceutical and PharmaMar (Spain) enter into a license agreement on anticancer agent, trabectedin
- Taiho History Museum completed at the Tokushima Plant
- Marketing approval obtained in Singapore for TS-ONE (TS-1)
- Taiho Pharmaceutical acquires Tsukuba Research Institute from Banyu Pharmaceutical Co., Ltd
|
|---|
| 2010 |
- Marketing approval for TS-1 obtained in Taiwan
|
|---|
| 2011 |
- TS-1 approved in the EU as a treatment for advanced gastric cancer
- Taiho Pharmaceutical signs a licensing agreement on a new antiemetic combination agent with Helsinn Healthcare S.A.
- Taiho Pharmaceutical signs a distribution agreement with MSD K.K. for the anticancer agent vorinostat in Japan
- Taiho Pharmaceutical signs a co-development and commercialization agreement with Nordic Group BV for Teysuno in Europe
- Taiho Pharma Singapore Pte. Ltd. (now TAIHO PHARMA ASIA PACIFIC PTE. LTD.) Established
|
|---|
| 2012 |
- Marketing of Teysuno begins in Europe
- Masayuki Kobayashi becomes president and representative director
- License agreement for anti-allergy drug bilastine signed with Spain-based Faes Farma S.A.
|
|---|
[2013-]
| 2013 |
- Kitajima Plant completed in Tokushima Prefecture
- Agreement signed on transfer of Astellas' fermentation research-related assets to Taiho
|
|---|
| 2014 |
- Name of US-based subsidiary changed from Taiho Pharma U.S.A., Inc. to Taiho Oncology, Inc.
|
|---|
| 2015 |
- Approval obtained from the U.S. FDA for the anticancer drug LONSURF (TAS-102) as a treatment for refractory metastatic colorectal cancer
- Marketing approval for TS-ONE obtained in Myanmar
|
|---|
| 2016 |
- Tiovita 3000 launched in Hong Kong
- Approval for LONSURF obtained in Europe
- TAIHO VENTURES, LLC established in California in the U.S.
- CTM Building (clinical trial materials manufacturing facility) completed at the Kitajima Plant
- TAIHO PHARMA CANADA, INC. established in Canada
|
|---|
| 2017 |
- Taiho Pharmaceutical Concludes Option and License Agreement with Arcus Biosciences
- Taiho Pharmaceutical Acquires Marketing Approval for LONSURF in Hong Kong and Taiwan
- Taiho Pharmaceutical Signs a Co-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan
|
|---|
| 2018 |
- HP building (Highly Potent Pharmaceutical Ingredients) completed at Saitama Site
- Approval for LONSURF obtained in Canada
|
|---|
| 2019 |
- Taiho Innovations, LLC, established in Japan
- Participated in READYFOR SDGs, using crowd funding to support organizations addressing issues in the field of oncology
- Taiho Pharmaceutical greenhouse gas emissions reduction Targets earn Science Based Targets (SBT) initiative certification
- Awarded gold prize at the Cancer Ally Awards 2019
|
|---|
| 2022 |
- Taiho Pharmaceutical and Cullinan Oncology announce strategic collaboration to jointly develop and commercialize CLN-081/TAS6417 and Taiho’s acquisition of Cullinan Pearl
- U.S. FDA approves FGFR Inhibitor, futibatinib for the treatment of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma
|
|---|
| 2023 |
- Approval of LYTGOBI for cholangiocarcinoma obtained in Europe (conditional marketing authorization)
- Approval for the combination therapy of LONSURF and bevacizumab for colorectal cancer obtained in Europe and the United States
- Awarded ”Gold” prize (5 years in a row) and “Best Practice” at the Cancer Ally Awards 2023
|
|---|
| 2024 |
- Entered into a licensing agreement with Haihe Biopharma for gumarontinib(SCC244), a treatment for non-small cell lung cancer
- Established ARIRGE Co., Ltd., a new company to address social issues related to cancer
|
|---|
